This study of 907 patients (largest single cohort study from India) showed an overall 23% EGFR mutation, with a rate of 26% in adenocarcinoma, in Indian population that closely approximates the rate in Japanese and East Asian countries. The gene discussed is EGFR; the disease is adenocarcinoma.